Introduction

For decades, wound care has been measured against a single milestone: closure. A wound that has re-epithelialized — skin has grown back over the defect — is typically recorded as “healed” on a discharge summary. But clinicians who manage chronic wounds, burns, and complex surgical sites know this milestone tells only part of the story. A closed wound can still be fragile, poorly vascularized, prone to breakdown, and cosmetically and functionally inferior to the tissue it replaced.

The real endpoint of wound care is not closure — it is tissue remodeling: the restoration of skin that is structurally sound, mechanically resilient, and functionally close to native tissue. This shift in perspective is increasingly shaping how advanced wound care programs at corporate hospitals evaluate the products and protocols they adopt.

Why Closure Alone Is an Incomplete Endpoint

Wound closure marks the point at which keratinocytes have migrated across the wound bed and formed a continuous epithelial layer. This is a necessary milestone, but several problems can exist beneath a closed surface:

For hospitals, these gaps translate into real clinical risk: wound dehiscence, recurrent ulceration at the same site, and follow-up visits or readmissions that a “closed” wound classification does not capture.

Remodeling: The Phase That Determines the Real Outcome

Wound Healing time line

Tissue remodeling is the process by which the body converts the provisional matrix of early wound repair into tissue that functions like the skin it replaced. It involves:

This phase can continue for a year or more after a wound first appears closed — which is exactly why treating closure as the finish line under-serves the patient, and why hospitals increasingly build post-closure follow-up into complex wound protocols.

Supporting the Full Journey: Why the Scaffold Matters

The quality of remodeling is heavily influenced by what happens earlier in the healing process — specifically, whether the wound bed had access to an extracellular matrix (ECM) capable of guiding organized repair from the outset. A wound that closes over a disorganized, protease-degraded matrix is set up for a poor remodeling phase, regardless of how quickly it closed.

This is the principle behind CholeDerm®, Alicorn Medical’s indigenously developed, CDSCO-approved (Class D) tissue-engineered ECM scaffold, created in collaboration with the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST). Manufactured through the enzyme-free, detergent-free PrisTINE Process, CholeDerm® preserves 154 biomolecules and the native ECM architecture — giving the wound bed the biological scaffolding to support not just closure, but organized, durable remodeling:

Wound Care Goal

How an Intact ECM Scaffold Supports It

Faster, cleaner closure

Structured cell migration and re-epithelialization

Stronger, more durable tissue

Supports organized Type I collagen deposition during remodeling

Reduced scarring and contracture

Guides regeneration rather than relying on contraction alone

Lower risk of breakdown or recurrence

Mature, well-vascularized tissue rather than fragile closure

What This Means for Hospital Wound Care Protocols

For corporate hospitals and multi-specialty wound care centers, shifting the internal benchmark from “closure” to “quality of remodeled tissue” has practical implications:

Conclusion

A wound that closes quickly but remodels poorly is not a healing success — it is a delayed complication. As Indian hospitals expand dedicated wound care and regenerative medicine programs, the clinical and administrative conversation is moving from “how fast did it close” to “how well did it remodel.” CholeDerm®, developed and manufactured in India, is built specifically to support that fuller definition of healing — from the first day of closure through the months of remodeling that follow.

Hospitals evaluating CholeDerm® for their wound care, surgical, or diabetic foot programs can reach Alicorn Medical’s team at technical@alicornmed.com or sales@alicornmed.com.

Access to this page is restricted to healthcare professionals to ensure that medical information is provided to the appropriate audience.

The details collected are solely for professional engagement and will not be shared or used for any other purpose.

Call Now Button

FAQ

Frequently Asked Questions

What is the Alicorn Medical Journal?+

The Alicorn Medical Journal is a medical device research resource published by Alicorn Medical, featuring clinical guides, wound care research, and articles on extracellular matrix (ECM) science for healthcare professionals in India.

What topics does the Journal cover?+

The Journal covers wound care and clinical practice, wound dressing selection, negative pressure wound therapy (NPWT), flap reconstructive surgery, and the science behind cholecyst-derived ECM scaffolds such as CholeDerm®.

Who writes the Journal articles?+

Articles are published by the Alicorn Medical team, with contributions from clinical authors.

Who is the Journal intended for?+

The Journal is intended for healthcare professionals, clinicians, and hospital procurement teams seeking evidence-based information on wound care and tissue-engineered scaffolds.

Is the Journal available in languages other than English?+

Yes. Journal content is available in multiple Indian languages, including Hindi, Tamil, Kannada, Telugu, Marathi, Gujarati, and Malayalam, in addition to English.

How often is the Journal updated?+

New articles are published regularly, covering current research and clinical guidance in wound care and regenerative medicine.